Treatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current systemic treatment often causes autoimmune side effects. In more than 50% of squamous cell cervical cancer, PD-L1 expression is detected. | DURVIT A phase-I trial of single low-dose durvalumab Medi4736 IntraTumourally injected in cervical cancer Safety toxicity and effect on the primary tumour and lymph node microenvironment
